T. Mesplède

M. Wainberg, Yingshan Han, T. Mesplède, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor

M. Wainberg, Wei‐Lie Xiao, Han-Dong Sun, 2015, Antiviral chemistry & chemotherapy.

HIV-1 subtype B integrase confers low-level

M. Wainberg, T. Mesplède, Vincent Cutillas, 2014 .

Integrase strand transfer inhibitors in the management of HIV-positive individuals

M. Wainberg, P. Quashie, T. Mesplède, 2014, Annals of medicine.

The Effect of HIV-1 Integrase Resistance Mutations when Introduced into 1

M. Wainberg, P. Quashie, Said A Hassounah, 2014 .

Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.

M. Wainberg, O. Delelis, E. Deprez, 2013, Antiviral research.

The POU Transcription Factor Oct-1 Represses Virus-Induced Interferon A Gene Expression

J. Doly, T. Mesplède, M. Island, 2005, Molecular and Cellular Biology.

The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.

M. Wainberg, S. Colby-Germinario, Said A Hassounah, 2015, The Journal of antimicrobial chemotherapy.

Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART

F. Nekka, S. Sanche, Jun Li, 2018, PloS one.

Inhibition of NF‐&kgr;B‐dependent HIV‐1 replication by the marine natural product bengamide A

M. Wainberg, David E. Williams, R. Andersen, 2018, Antiviral research.

Identification of resveratrol analogs as potent anti‐dengue agents using a cell‐based assay

M. Wainberg, P. Crooks, Yingshan Han, 2017, Journal of medical virology.

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

M. Wainberg, P. Quashie, Yingshan Han, 2015, PloS one.

The E3 Ubiquitin Ligase Triad3A Negatively Regulates the RIG-I/MAVS Signaling Pathway by Targeting TRAF3 for Degradation

Qiang Sun, C. Ware, J. Hiscott, 2009, PLoS pathogens.

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

H. Pham, Yingshan Han, T. Mesplède, 2019, Journal of medical virology.

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

Yingshan Han, T. Mesplède, 2018, Expert opinion on investigational drugs.

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

M. Wainberg, Yingshan Han, T. Mesplède, 2018, Journal of medical virology.

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

H. Pham, T. Mesplède, 2019, Expert opinion on pharmacotherapy.

Integrase Strand Transfer Inhibitors in HIV Therapy

M. Wainberg, T. Mesplède, 2013, Infectious Diseases and Therapy.

The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir

M. Wainberg, Said A Hassounah, T. Mesplède, 2014, Antimicrobial Agents and Chemotherapy.

Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity

M. Wainberg, T. Mesplède, Diane N. Singhroy, 2015, Antimicrobial Agents and Chemotherapy.

Productive Entry of HIV-1 during Cell-to-Cell Transmission via Dynamin-Dependent Endocytosis

M. Wainberg, J. Münch, T. Mesplède, 2013, Journal of Virology.

Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase

M. Wainberg, P. Quashie, Tamar Veres, 2013, Antimicrobial Agents and Chemotherapy.

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

T. Mesplède, 2021, Expert opinion on pharmacotherapy.

A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration

M. Wainberg, F. Nekka, S. Sanche, 2017, CPT: pharmacometrics & systems pharmacology.

Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes

M. Wainberg, J. Lifson, B. Keele, 2018, Journal of Virology.

Proceedings of the Frontiers of Retrovirology Conference 2016

R. König, D. Elleder, R. Sachidanandam, 2016, Retrovirology.

HIV drug resistance against strand transfer integrase inhibitors

M. Wainberg, T. Mesplède, Kaitlin Anstett, 2017, Retrovirology.

HIV Drug Resistance and the Advent of Integrase Inhibitors

M. Wainberg, P. Quashie, T. Mesplède, 2013, Current Infectious Disease Reports.

M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA

M. Wainberg, B. Brenner, T. Mesplède, 2017, The Journal of antimicrobial chemotherapy.

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review

M. Wainberg, Said A Hassounah, T. Mesplède, 2016, Pathogens & immunity.

Transcriptional re‐programming of primary macrophages reveals distinct apoptotic and anti‐tumoral functions of IRF‐3 and IRF‐7

J. Hiscott, R. Romieu-Mourez, D. Leaman, 2009, European journal of immunology.

Insertion as resistance mechanism against integrase inhibitors in several retroviruses.

B. Keele, H. Pham, Said A Hassounah, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Investigational HIV integrase inhibitors in phase I and phase II clinical trials

M. Wainberg, Yingshan Han, T. Mesplède, 2017, Expert opinion on investigational drugs.

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir

M. Wainberg, B. Brenner, T. Mesplède, 2015, AIDS.

The development of novel HIV integrase inhibitors and the problem of drug resistance.

M. Wainberg, P. Quashie, T. Mesplède, 2012, Current opinion in virology.

IκB Kinase ε-Dependent Phosphorylation and Degradation of X-Linked Inhibitor of Apoptosis Sensitizes Cells to Virus-Induced Apoptosis

Qiang Sun, J. Hiscott, R. Lin, 2011, Journal of Virology.

Evolution of HIV integrase resistance mutations

M. Wainberg, P. Quashie, T. Mesplède, 2012, Current opinion in infectious diseases.

Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout.

M. Wainberg, P. Quashie, Nathan Osman, 2015, The Journal of antimicrobial chemotherapy.

Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.

Jing Leng, M. Soares, J. Routy, 2020, The Journal of antimicrobial chemotherapy.

Reply to Darcis and Berkhout.

C. Boucher, H. Pham, D. A. van de Vijver, 2018, The Journal of infectious diseases.

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

C. Boucher, H. Pham, D. A. van de Vijver, 2018, The Journal of infectious diseases.

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1

M. Wainberg, B. Brenner, A. Alikhani, 2017, Antimicrobial Agents and Chemotherapy.

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir

M. Wainberg, B. Brenner, H. Pham, 2016, AIDS.

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.

M. Wainberg, B. Brenner, E. Martinez, 2016, The Journal of antimicrobial chemotherapy.

Dolutegravir inhibits HIV-1 Env evolution in primary human cells

M. Wainberg, B. Brenner, T. Mesplède, 2015, AIDS.

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

M. Wainberg, T. Mesplède, Maureen Oliveira, 2015, Journal of Virology.

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

M. Wainberg, P. Quashie, Nathan Osman, 2014, The Journal of antimicrobial chemotherapy.

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

M. Wainberg, T. Mesplède, 2014, Viruses.

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

M. Wainberg, P. Quashie, T. Mesplède, 2014, AIDS.

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

M. Wainberg, P. Quashie, Nathan Osman, 2014, Retrovirology.

What if HIV were unable to develop resistance against a new therapeutic agent?

M. Wainberg, F. Raffi, T. Mesplède, 2013, BMC Medicine.

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

M. Wainberg, C. Petropoulos, Wei Huang, 2013, Retrovirology.

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

M. Wainberg, T. Fujiwara, P. Quashie, 2011, Journal of Virology.

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

C. Tremblay, B. Brenner, D. Rouleau, 2018, Retrovirology.

Chapter 3 HIV-1 resistance dynamics in patients with virological failure to dolutegravir maintenance monotherapy .

C. Boucher, R. Schuurman, T. Mesplède, 2018 .

Will LEDGIN molecules be able to play a role in a cure for HIV infection?

M. Wainberg, T. Mesplède, 2016, EBioMedicine.

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration

Jing Leng, M. Wainberg, H. Pham, 2017, mBio.

Investigational drugs for HIV: trends, opportunities and key players

T. Mesplède, R. J. Overmars, Zoë Krullaars, 2023, Expert opinion on investigational drugs.

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

M. Wainberg, H. Pham, T. Mesplède, 2016, Retrovirology.

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance

M. Wainberg, T. Mesplède, Maureen Oliveira, 2015, Journal of Virology.

Might dolutegravir be part of a functional cure for HIV?

M. Wainberg, Yingshan Han, T. Mesplède, 2016, Canadian journal of microbiology.

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

B. Brenner, J. Routy, M. Robbins, 2018, Retrovirology.

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

M. Wainberg, T. Mesplède, 2015, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

The latest evidence for possible HIV-1 curative strategies

H. Pham, T. Mesplède, 2018, Drugs in context.

The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors

M. Wainberg, B. Brenner, C. Boucher, 2018, The Journal of infectious diseases.

Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout

M. Wainberg, B. Brenner, Nathan Osman, 2018, AIDS.

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

M. Wainberg, H. Pham, T. Mesplède, 2016, Retrovirology.

Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase

M. Wainberg, P. Quashie, Tamar Veres, 2014, Antimicrobial Agents and Chemotherapy.

A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence.

M. Wainberg, P. Quashie, Yingshan Han, 2012, Journal of virological methods.

OPINION Evolution of HIV integrase resistance mutations

M. Wainberg, P. Quashie, T. Mesplède, 2012 .

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239

M. Wainberg, B. Brenner, D. Moisi, 2015, Journal of Virology.

Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors

M. Wainberg, Said A Hassounah, T. Mesplède, 2015, Antimicrobial Agents and Chemotherapy.

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1

M. Wainberg, Yingshan Han, T. Mesplède, 2017, Journal of Virology.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency

M. Wainberg, T. Mesplède, D. Donahue, 2014, Viruses.

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy

T. Mahmoudi, E. van Nood, H. Bax, 2023, Science advances.

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity

M. Wainberg, J. Falgueyret, P. Quashie, 2013, Retrovirology.

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.

M. Wainberg, T. Mesplède, R. Fusco, 2016, The Journal of antimicrobial chemotherapy.

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

M. Wainberg, T. Mesplède, R. Fusco, 2015, Journal of Virology.

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus.

Yingshan Han, T. Mesplède, J. Yue, 2020, Journal of natural products.

HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase

M. Wainberg, B. Brenner, D. Moisi, 2014, Antimicrobial Agents and Chemotherapy.

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

J. Archambault, F. Coutlée, T. Mesplède, 2011, Journal of Virology.

HIV drug resistance against strand transfer integrase inhibitors

M. Wainberg, B. Brenner, T. Mesplède, 2017, Retrovirology.

HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity

M. Wainberg, B. Brenner, T. Mesplède, 2017, Journal of Virology.

Repression by Homeoprotein Pitx1 of Virus-Induced Interferon A Promoters Is Mediated by Physical Interaction and trans Repression of IRF3 and IRF7

J. Drouin, P. Djian, T. Mesplède, 2002, Molecular and Cellular Biology.

A resveratrol analog termed 3,3′,4,4′,5,5′‐hexahydroxy‐trans‐stilbene is a potent HIV‐1 inhibitor

M. Wainberg, T. Szekeres, W. Jaeger, 2015, Journal of medical virology.

Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study

M. Wainberg, B. Brenner, Nathan Osman, 2017, AIDS Research and Therapy.

Vesicular Stomatitis Virus Oncolysis of T Lymphocytes Requires Cell Cycle Entry and Translation Initiation

N. Sonenberg, J. Hiscott, J. Bell, 2008, Journal of Virology.

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs

M. Wainberg, S. Fafi-Kremer, T. Mesplède, 2018, The Journal of antimicrobial chemotherapy.

Proceedings of the Frontiers of Retrovirology Conference 2016

Sebastian A. Wagner, R. König, D. Elleder, 2016, Retrovirology.

The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B

M. Wainberg, P. Quashie, Nathan Osman, 2015, AIDS.

HIV-1 Group O Resistance Against Integrase Inhibitors

M. Wainberg, B. Brenner, D. Moisi, 2015, Journal of acquired immune deficiency syndromes.

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity

M. Wainberg, J. Falgueyret, P. Quashie, 2013, Retrovirology.

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report

S. van Boheemen, H. Pham, Sunbin Yoo, 2022, Journal of global antimicrobial resistance.

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

M. Wainberg, P. Quashie, T. Mesplède, 2014, AIDS.

HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity

M. Wainberg, B. Brenner, T. Mesplède, 2017, Journal of Virology.

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.

M. Wainberg, Yingshan Han, T. Mesplède, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

HIV-1 Resistance to Integrase Inhibitors

M. Wainberg, Yingshan Han, T. Mesplède, 2017 .

HIV-1 group O integrase displays lower enzymatic efficiency and higher

M. Wainberg, B. Brenner, D. Moisi, 2014 .

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

J. Archambault, F. Coutlée, T. Mesplède, 2011, Journal of Virology.

Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness

M. Wainberg, T. Seki, P. Quashie, 2012 .

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.

M. Wainberg, B. Brenner, E. Martinez, 2016, The Journal of antimicrobial chemotherapy.

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

H. Pham, T. Mesplède, Meng A Xiao, 2023, Antimicrobial Agents and Chemotherapy.

M. Wainberg, T. Mesplède, R. Fusco, 2015, Journal of Virology.

Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor

M. Wainberg, Wei‐Lie Xiao, Han-Dong Sun, 2015, Antiviral Chemistry & Chemotherapy.